ACCC Flags Phase 2 Review for Zoetis' Neogen Genomics Deal
ZTS is trading near its 52-week low of $71.47 (5.4% above the low).
Summary
Australia's competition regulator is escalating its review of Zoetis' acquisition of Neogen Genomics to a Phase 2, signaling deeper scrutiny. The ACCC is specifically examining the competitive impact of Zoetis gaining access to a larger volume of genetic data on Australian cattle. This adds regulatory risk to a deal that was announced amid a backdrop of lowered guidance and a class action lawsuit. Submissions are due by July 31, with no conclusion yet reached. The extended review could delay or complicate the acquisition, which was intended to bolster Zoetis' diagnostics capabilities following the recent VitalRADS purchase.
At the time of this announcement, ZTS was trading at $75.31 on NYSE in the Life Sciences sector, with a market capitalization of approximately $32.2B. The 52-week trading range was $71.47 to $160.48. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.